StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) company profile

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.35+0.10 (+8.00%)

Close on Nov 17, 2026Market cap $172.35MP/E –Yield –

About ADC Therapeutics

Pharmaceutical Preparations, SIC 2834

ADC Therapeutics is a commercial-stage biotechnology company focused on developing antibody drug conjugates to treat cancer. Its primary commercial product is ZYNLONTA, a CD19-directed therapy approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma who have received two or more lines of systemic treatment. The company also investigates expanded clinical applications for ZYNLONTA across earlier therapy lines and combinations, while advancing pipeline candidates such as ADCT-241 for prostate cancer. In the United States, it commercializes its medicine directly through pharmaceutical wholesale distributors that supply hospitals and oncology healthcare providers.

The enterprise maintains an international presence through strategic agreements and operational hubs. Its commercial partnerships and licensing arrangements cover markets across Europe, Japan, China, and Canada, while third-party contract manufacturing organizations produce its therapeutic compounds. ADC Therapeutics is headquartered in Lausanne, Switzerland, and runs operational facilities in New Jersey.

Summary of the business section of ADC Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
ADC Therapeutics SA
Headquarters
Epalinges, V8
Address
Biopole, Route De La Corniche 3b 1066
Phone
41 21 653 02 00
Employees
188, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
V8
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers SA, Lausanne, Switzerland

Stock & identifiers

Ticker
ADCT
Exchange
NYSE
IPO date
May 18, 2020
Shares outstanding
128M, Aug 3, 2026
Public float
$136.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1771910
CUSIP
H0036K147
FIGI
BBG00Q6Q3QX1
Share class FIGI
BBG00Q6Q3RN0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ameet MallikChief Executive Officer, Director2,790,870
Mohamed ZakiChief Medical Officer896,317
Peter J. GrahamChief Legal Officer841,640
Jose CarmonaChief Financial Officer938,076
Lisa Michelle KalleboChief Accounting Officer128,224
Viviane MongesDirector186,447
Victor SandorDirector140,686
Robert AzelbyDirector112,805
Timothy CoughlinDirector72,400
Jean-Pierre BizzariDirector139,302
Ron SquarerDirector123,431
Peter HugDirector263,344

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.45M$6.05M$1.38M$92–
FY2024$1.84M$4.13M$971.55K$52–
FY2023$3.78M$2.68M$2.83M$43–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Ameet Mallik
Chief Executive Officer
$776.08K$1.05M$582.06K$48.50K$2.45M+33%
Jose “Pepe” Carmona
Chief Financial Officer
$525.21K$386.40K$328.26K$7.14K$1.25M+34%
Mohamed Zaki
Chief Medical Officer
$690.12K$370.30K$431.33K$23.82K$1.52M+50%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 18, 2020
Offer price
$19.00
Securities offered
12,245,631
Gross proceeds
$232.67M
Exchange
NYSE
First trading day
May 15, 2020
First-day close
$29.65+56.1%
Lock-up ends (est.)
Nov 11, 2020

“The initial public offering price is $19.00 per common share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 188 full-time employees and five part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?